InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program
Transition to INM-755 Expected to Improve the Probability of Development and Regulatory Success Initiation of a Phase I Clinical Trial...





